The influence of 5-aminosalicylic acid on the progression of colorectal adenomas via the ß-catenin signaling pathway

Carcinogenesis

Volumn 33, Issue 3, 2012, Pages 637-643

  Munding, Johanna ^a   Ziebarth, Wibke ^a   Pox, Christian P ^b   Ladigan, Svetlana ^a   Reiser, Markus ^c   Hüppe, Dietrich ^d   Brand, Linda ^b   Schmiegel, Wolff ^a,b,e   Tannapfel, Andrea ^a   Reinacher Schick, Anke C ^a,b  

^a RUHR UNIVERSITY BOCHUM   (Germany)

^b RUHR UNIVERSITY BOCHUM   (Germany)

^c Paracelsus Klinik Marl   (Germany)

^d Clinic for Gastroenterology and Endoscopy   (Germany)

^e RUHR UNIVERSITY BOCHUM   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

BETA CATENIN; CYCLIN D1; CYCLOOXYGENASE 2; MESALAZINE; ORNITHINE DECARBOXYLASE; T CELL FACTOR PROTEIN; UVOMORULIN; WNT PROTEIN;

ADULT; ARTICLE; CANCER GROWTH; CANCER LOCALIZATION; CANCER RISK; COLON CANCER; COLON MUCOSA; COLONOSCOPY; COLORECTAL ADENOMA; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; IN VIVO STUDY; MAJOR CLINICAL STUDY; MALE; MORPHOMETRICS; MULTICENTER STUDY; NUCLEAR LOCALIZATION SIGNAL; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; WESTERN BLOTTING;

EID: 84857981803     PISSN: 01433334     EISSN: 14602180     Source Type: Journal    
DOI: 10.1093/carcin/bgr306     Document Type: Article

References (38)

1. Fearon, E.R. et al. (1990) A genetic model for colorectal tumorigenesis. Cell, 61, 759-767.
2. Konishi, K. et al. (2004) Molecular differences between sporadic serrated and conventional colorectal adenomas. Clin. Cancer Res., 10, 3082-3090.
3. Li, D. et al. (2009) Association of large serrated polyps with synchronous advanced colorectal neoplasia. Am. J. Gastroenterol., 104, 695-702.
4. Oh, K. et al. (2005) Support for hMLH1 and MGMT silencing as a mechanism of tumorigenesis in the hyperplastic-adenoma-carcinoma (serrated) carcinogenic pathway in the colon. Hum. Pathol., 36, 101-111.
5. Schmiegel, W. et al. (2008) [Update S3-guideline "colorectal cancer" 2008]. Z. Gastroenterol., 46, 799-840.
6. Eaden, J. et al. (2000) Colorectal cancer prevention in ulcerative colitis: a case-control study. Aliment. Pharmacol. Ther., 14, 145-153.
7. Ekbom, A. et al. (1990) Ulcerative colitis and colorectal cancer. A population-based study. N. Engl. J. Med., 323, 1228-1233.
8. Moody, G.A. et al. (1996) Long-term therapy with sulphasalazine protects against colorectal cancer in ulcerative colitis: a retrospective study of colorectal cancer risk and compliance with treatment in Leicestershire. Eur. J. Gastroenterol. Hepatol., 8, 1179-1183.
9. Rubin, D.T. et al. (2006) Aminosalicylate therapy in the prevention of dysplasia and colorectal cancer in ulcerative colitis. Clin. Gastroenterol. Hepatol., 4, 1346-1350.
10. van Staa, T.P. et al. (2005) 5-Aminosalicylate use and colorectal cancer risk in inflammatory bowel disease: a large epidemiological study. Gut, 54, 1573-1578.
11. Brown, W.A. et al. (2000) 5-Aminosalicyclic acid and olsalazine inhibit tumor growth in a rodent model of colorectal cancer. Dig. Dis. Sci., 45, 1578-1584.
12. Davis, A.E. et al. (1992) The effect of therapeutic drugs used in inflammatory bowel disease on the incidence and growth of colonic cancer in the dimethylhydrazine rat model. Br. J. Cancer, 66, 777-780.
13. Bus, P.J. et al. (1999) Mesalazine-induced apoptosis of colorectal cancer: on the verge of a new chemopreventive era? Aliment. Pharmacol. Ther., 13, 1397-1402.
14. Reinacher-Schick, A. et al. (2003) Mesalazine causes a mitotic arrest and induces caspase-dependent apoptosis in colon carcinoma cells. Carcinogenesis, 24, 443-451.
15. Schmiegel, W. et al. (2004) Effect of 5-aminosalicylate (5-ASA) on the recurrence rate of sporadic colorectal adenomas. Gastroenterology, 126, A452.
16. Reinacher-Schick, A. et al. (2000) Mesalazine changes apoptosis and proliferation in normal mucosa of patients with sporadic polyps of the large bowel. Endoscopy, 32, 245-254.
17. Bantel, H. et al. (2000) Mesalazine inhibits activation of transcription factor NF-kappaB in inflamed mucosa of patients with ulcerative colitis. Am. J. Gastroenterol., 95, 3452-3457.
18. Charalambous, M.P. et al. (2003) Upregulation of cyclooxygenase-2 is accompanied by increased expression of nuclear factor-kappa B and I kappa B kinase-alpha in human colorectal cancer epithelial cells. Br. J. Cancer, 88, 1598-1604.
19. Egan, L.J. et al. (1999) Inhibition of interleukin-1-stimulated NF-kappaB RelA/p65 phosphorylation by mesalamine is accompanied by decreased transcriptional activity. J. Biol. Chem., 274, 26448-26453.
20. Kaiser, G.C. et al. (1999) Mesalamine blocks tumor necrosis factor growth inhibition and nuclear factor kappaB activation in mouse colonocytes. Gastroenterology, 116, 602-609.
21. Bos, C.L. et al. (2006) Protein phosphatase 2A is required for mesalazinedependent inhibition of Wnt/beta-catenin pathway activity. Carcinogenesis, 27, 2371-2382.
22. Aberle, H. et al. (1997) beta-catenin is a target for the ubiquitin-proteasome pathway. EMBO J., 16, 3797-3804.
23. Wong, N.A. et al. (2002) Beta-catenin-a linchpin in colorectal carcinogenesis? Am. J. Pathol., 160, 389-401.
24. Shtutman, M. et al. (1999) The cyclin D1 gene is a target of the betacatenin/LEF-1 pathway. Proc. Natl Acad. Sci. USA, 96, 5522-5527.
25. Gottardi, C.J. et al. (2001) E-cadherin suppresses cellular transformation by inhibiting beta-catenin signaling in an adhesion-independent manner. J. Cell Biol., 153, 1049-1060.
26. Gottardi, C.J. et al. (2001) Adhesion signaling: how beta-catenin interacts with its partners. Curr. Biol., 11, R792-R794.
27. Korinek, V. et al. (1997) Constitutive transcriptional activation by a betacatenin-Tcf complex in APC-/- colon carcinoma. Science, 275, 1784-1787.
28. Bartkova, J. et al. (1994) Cell cycle-related variation and tissue-restricted expression of human cyclin D1 protein. J. Pathol., 172, 237-245.
29. Masunaga, R. et al. (2000) Cyclooxygenase-2 expression correlates with tumor neovascularization and prognosis in human colorectal carcinoma patients. Clin. Cancer Res., 6, 4064-4068.
30. Valizadeh, A. et al. (1997) Expression of E-cadherin-associated molecules (alpha-, beta-, and gamma-catenins and p120) in colorectal polyps. Am. J. Pathol., 150, 1977-1984.
31. Day, D.W. et al. (1978) The adenoma-carcinoma sequence. Major Probl. Pathol., 10, 58-71.
32. Ritland, S.R. et al. (1999) Evaluation of 5-aminosalicylic acid (5-ASA) for cancer chemoprevention: lack of efficacy against nascent adenomatous polyps in the Apc(Min) mouse. Clin. Cancer Res., 5, 855-863.
33. Dehari, R. (2001) Infrequent APC mutations in serrated adenoma. Tohoku J. Exp. Med., 193, 181-186.
34. Fogt, F. et al. (2002) Genetic alterations in serrated adenomas: comparison to conventional adenomas and hyperplastic polyps. Hum. Pathol., 33, 87-91.
35. Yamamoto, T. et al. (2003) No major tumorigenic role for beta-catenin in serrated as opposed to conventional colorectal adenomas. Br. J. Cancer, 89, 152-157.
36. Hao, X. et al. (1997) Reduced expression of molecules of the cadherin/catenin complex in the transition from colorectal adenoma to carcinoma. Anticancer Res., 17, 2241-2247.
37. Brabletz, T. et al. (1998) Nuclear overexpression of the oncoprotein betacatenin in colorectal cancer is localized predominantly at the invasion front. Pathol. Res. Pract., 194, 701-704.
38. Araki, Y. et al. (2003) Regulation of cyclooxygenase-2 expression by the Wnt and ras pathways. Cancer Res., 63, 728-734.